Literature DB >> 19379294

Veterinary Co-operative Oncology Group - Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0.

.   

Abstract

Entities:  

Year:  2004        PMID： 19379294     DOI： 10.1111/j.1476-5810.2004.0053b.x

Source DB:  PubMed          Journal:  Vet Comp Oncol        ISSN： 1476-5810            Impact factor:   2.613


× No keyword cloud information.
  78 in total

1.  Phase I/II clinical trial of 2-difluoromethyl-ornithine (DFMO) and a novel polyamine transport inhibitor (MQT 1426) for feline oral squamous cell carcinoma.

Authors:  K A Skorupski; T G O'Brien; T Guerrero; C O Rodriguez; M R Burns
Journal:  Vet Comp Oncol       Date:  2011-03-08       Impact factor: 2.613

2.  Treatment of feline gastrointestinal small-cell lymphoma with chlorambucil and glucocorticoids.

Authors:  Timothy J Stein; Mackenzie Pellin; Howard Steinberg; Ruthanne Chun
Journal:  J Am Anim Hosp Assoc       Date:  2010 Nov-Dec       Impact factor: 1.023

3.  Evaluation of toxicity of a chronic alternate day metronomic cyclophosphamide chemotherapy protocol in dogs with naturally occurring cancer.

Authors:  Arata Matsuyama; J Paul Woods; Anthony J Mutsaers
Journal:  Can Vet J       Date:  2017-01       Impact factor: 1.008

Review 4.  Chemotherapy: managing side effects and safe handling.

Authors:  Valerie MacDonald
Journal:  Can Vet J       Date:  2009-06       Impact factor: 1.008

5.  First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study.

Authors:  Veronica Marchetti; Mario Giorgi; Anna Fioravanti; Riccardo Finotello; Simonetta Citi; Bastianina Canu; Paola Orlandi; Teresa Di Desidero; Romano Danesi; Guido Bocci
Journal:  Invest New Drugs       Date:  2011-04-21       Impact factor: 3.850

6.  Chemotherapy and radiation therapy in 4 dogs with muscle-invasive transitional cell carcinoma of the urinary tract.

Authors:  Laura Marconato; Dagmar B Nitzl; Katja J Melzer-Ruess; Marcel A Keller; Julia Buchholz
Journal:  Can Vet J       Date:  2012-08       Impact factor: 1.008

7.  Carboplatin versus alternating carboplatin and doxorubicin for the adjuvant treatment of canine appendicular osteosarcoma: a randomized, phase III trial.

Authors:  K A Skorupski; J M Uhl; A Szivek; S D Allstadt Frazier; R B Rebhun; C O Rodriguez
Journal:  Vet Comp Oncol       Date:  2013-10-04       Impact factor: 2.613

8.  The impact of carboplatin and toceranib phosphate on serum vascular endothelial growth factor (VEGF) and metalloproteinase-9 (MMP-9) levels and survival in canine osteosarcoma.

Authors:  Tracy L Gieger; Julie Nettifee-Osborne; Briana Hallman; Chad Johannes; Dawn Clarke; Michael W Nolan; Laurel E Williams
Journal:  Can J Vet Res       Date:  2017-07       Impact factor: 1.310

9.  Cytokine-Enhanced Vaccine and Interferon-β plus Suicide Gene Therapy as Surgery Adjuvant Treatments for Spontaneous Canine Melanoma.

Authors:  Liliana M E Finocchiaro; Chiara Fondello; María L Gil-Cardeza; Úrsula A Rossi; Marcela S Villaverde; María D Riveros; Gerardo C Glikin
Journal:  Hum Gene Ther       Date:  2015-05-26       Impact factor: 5.695

10.  Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma.

Authors:  Rebecca A Barnard; Luke A Wittenburg; Ravi K Amaravadi; Daniel L Gustafson; Andrew Thorburn; Douglas H Thamm
Journal:  Autophagy       Date:  2014-05-20       Impact factor: 16.016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.